Rosai-Dorfman-Destombes disease

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Section editor
Gaurav Goyal, MD
Birmingham, AL, USA

1 regimens on this page
1 variants on this page


Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

Consensus guidelines


All lines of therapy

Cobimetinib monotherapy


FDA-recommended dose
Study Dates of enrollment Evidence
Diamond et al. 2019 (MSK 15-216) 2016-NR Phase 2, fewer than 20 pts in this arm (RT)

Note: there were N=2 patients with this type of histiocytosis.

Targeted therapy

28-day cycles


  1. MSK 15-216: Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-524. Epub 2019 Mar 13. link to original article contains dosing details in manuscript link to PMC article PubMed NCT02649972